Novo integrated sciences' subsidiary, clinical consultants international, signs consulting agreement with pharmaceutical research & development company, sarfez pharmaceuticals, inc.

Bellevue, wash.--( business wire )--novo integrated sciences, inc. (nasdaq: nvos) (the “company” or “novo”), and clinical consultants international llc (“cci”), a novo wholly-owned subsidiary, today announced the signing of a consulting agreement (the “agreement”) with sarfez pharmaceuticals, inc. (“sarfez”), a pharmaceutical research and development company with an fda-approved edema treatment for patients with heart failure and renal disease.
NVOS Ratings Summary
NVOS Quant Ranking